Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology.
- Trial name
- NCT00317486
- Testing
- bosentan
- Volunteers
- 54 people
- Sponsor
- Actelion
Pulmonary Hypertension
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure.
- Trial name
- NCT04055415
- Testing
- adipose derived mesenchymal stem cells, Conventional drug therapy（expectorant，bronchodilator）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Liaocheng People's Hospital
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and…
- Trial name
- NCT05618093
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Hypertension, Pulmonary
Insulin Resistance in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in…
- Trial name
- NCT00825266
- Testing
- bosentan, Pioglitazone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) >20 mm Hg with a pulmonary arterial wedge pressure (PAWP) ≤15 mm Hg and…
- Trial name
- NCT07214129
- Testing
- Nebulized nitroglycerin
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Mansoura University
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart.
- Trial name
- SOTERIA (NCT07218029)
- Testing
- Sotatercept
- Where
- 137 sites in United States, Argentina and 25 more
- Volunteers
- 815 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension (PAH)
(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to…
- Trial name
- RightHeartIII (NCT03362047)
- Testing
- Riciguat Group, Macitentan Group
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- University of Giessen
Pulmonary Arterial Hypertension
Oral Iron Supplementation in Pulmonary Hypertension
The purpose of this study is to investigate the effects of iron supplementation in patients with pulmonary arterial hypertension and iron deficiency.
- Trial name
- NCT01446848
- Testing
- iron supplement
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Cleveland Clinic
Pulmonary Hypertension
The Role of Endothelin in Pulmonary Hypertension
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
- Trial name
- NCT00759408
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension
Based on existing literature and clinical trials, 2- hydroxbenzylamine (2-HOBA) has clear impact on mechanisms that much of the international field of pulmonary hypertension (PH) research agrees are central to disease…
- Trial name
- NCT06176118
- Testing
- 2-HOBA
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University Medical Center
Heart Failure, Chronic Obstructive Pulmonary Disease
Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational Study
This is a multicentric, prospective, observational study with two cohorts and adjunctive procedure. It aims at collecting and analyzing data about the function of an innovative hospital-territory integration health service for…
- Conditions
- Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, Pneumonia
- Trial name
- PRIME (NCT05723185)
- Testing
- Outpatient visit
- Where
- Italy
- Volunteers
- 246 people
- Sponsor
- Rovere Querini Patrizia
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH)
Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes…
- Trial name
- NCT07082933
- Testing
- Standard medical treatment
- Volunteers
- 5,000 people
- Sponsor
- Xijing Hospital
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension, Cardiovascular Diseases
Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.
Although there has been some progress in pharmacological management of PAH, limited functional capacity and low survival still persist, but there is evidence that exercise training can be accomplished without adverse effects or…
- Conditions
- Pulmonary Arterial Hypertension, Cardiovascular Diseases, Respiratory Disease, Hypertension, Pulmonary
- Trial name
- PAH (NCT03476629)
- Testing
- Physical activity
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Nove de Julho
Pulmonary Arterial Hypertension, Systemic Sclerosis
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds.
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus
- Trial name
- VOC-PAH (NCT03819777)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy.
- Trial name
- NCT05975905
- Testing
- Dose A KER-012, Dose B KER-012, Dose C KER-012
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 113 people
- Sponsor
- Keros Therapeutics, Inc.
Thalassemia Major, Thalassemia Intermedia
Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
This is a multicenter observational case-control analysis lasting 12 months aimed at determining the prevalence of pulmonary hypertension (PAH) in patients with Thalassemia Major and Intermedia.
- Conditions
- Thalassemia Major, Thalassemia Intermedia, Pulmonary Arterial Hypertension
- Trial name
- PAH2010 (NCT01496963)
- Testing
- Physician standard-of-care according to ESC/ERS Guidelines
- Where
- 8 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Idiopathic Pulmonary Arterial Hypertension
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb® Ig flex adsorber treatment (as an add-on to conventional treatment) used exclusively with the LIFE 18® apheresis system for…
- Trial name
- NCT01613287
- Testing
- TheraSorb® - Ig flex
- Where
- 4 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Miltenyi Biotec B.V. & Co. KG